SignalFDA/Bio
Lexicon Pharmaceuticals Provides Update on Baseline Patient Characteristics for Pivotal Phase 3 SONATA-HCM Study of Sotagliflozin in Symptomatic Hypertrophic Cardiomyopathy
Lexicon updates baseline characteristics for pivotal Phase 3 SONATA-HCM sotagliflozin study in hypertrophic cardiomyopat
Context
What happened: Lexicon Pharmaceuticals (Nasdaq: LXRX) released baseline patient characteristics for the pivotal Phase 3 SONATA-HCM study of sotagliflozin in symptomatic hypertrophic cardiomyopathy, with data to be presented October 24, 2026 at the International HCM Summit in Boston.
Key numbers: 542
Why it matters: Lexicon states the over enrollment may enhance the study's statistical power to detect treatment effects on the primary endpoint of KCCQ-CSS change at Week 26. The company notes patients with non-obstructive disease currently have no FDA-approved disease-specific treatments.
Market: -4.5% today ($1.49), +30.7% YTD — as of 13:33 UTC
What changed
Lexicon Pharmaceuticals (Nasdaq: LXRX) released baseline patient characteristics for the pivotal Phase 3 SONATA-HCM study of sotagliflozin in symptomatic hypertrophic cardiomyopathy, with data to be presented October 24, 2026 at the International HCM Summit in Boston.
Why it matters
Lexicon states the over enrollment may enhance the study's statistical power to detect treatment effects on the primary endpoint of KCCQ-CSS change at Week 26. The company notes patients with non-obstructive disease currently have no FDA-approved disease-specific treatments.
Market: -4.5% today ($1.49), +30.7% YTD — as of 13:33 UTC